Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vx 001

Drug Profile

Vx 001

Alternative Names: hTERT572Y/hTERT572; Human telomerase reverse transcriptase 572Y; TERT572Y; Vx-001; Vx-001/hTERT

Latest Information Update: 05 Feb 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vaxon Biotech
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action Immunostimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • No development reported Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 31 Jan 2018 Vx 001 is still at phase II development stage for Non-small cell lung cancer in Czech Republic, France, Germany, Greece, Italy, Poland, Romania and Spain (SC) (Vaxon Biotech pipeline, January 2018)
  • 07 Sep 2015 Vx 001 is still in phase II trials for Non-small cell lung cancer in Greece
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top